Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France
Copyright © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved..
OBJECTIVES: We investigated the impact of the COVID-19 and national pandemic response on the epidemiology of Extended Spectrum Beta-Lactamase producing E. coli (ESBL-E.coli) in France.
METHODS: Individual microbiology records from clinical laboratories were analyzed between 1 January 2019 to 31 December 2020. The ESBL-E.coli rates from clinical samples of patients in primary care and nursing home residents were compared before and after the general lockdown in March 2020, according to demographic and geographical characteristics. Interrupted time series analyses were performed to detect measurable changes in the trend of ESBL-E.coli rates.
RESULTS: Records covering 793,954 E. coli isolates from 1022 clinical laboratories were analyzed. In primary care, 3.1% of E. coli isolates from clinical samples were producing ESBL before March 2020 and 2.9% since May 2020 (p < 0.001). The proportion of ESBL-E.coli decreased significantly among urine cultures, females, age categories 5-19, 40-64, > 65 year-old, and in the North, West, East and South-East regions. In nursing home, the ESBL-E.coli rate was 9.3% (monthly rate min-max: 6.5-10.5%) before March 2020 and 8.3% (7.2-9.1%) since May 2020 (p < 0.001). The reduction rate accelerated from -0.04%/month to -0.22%/month from May 2020 (p < 0.001).
CONCLUSION: Investigation of factors that led to the decreased proportion of ESBL-E.coli during the COVID-19 pandemic is urgently needed.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
The Journal of infection - 83(2021), 6 vom: 12. Dez., Seite 664-670 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lemenand, Olivier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 25.09.2022 published: Print-Electronic CommentIn: J Infect. 2022 Jul;85(1):90-122. - PMID 35378141 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.09.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331413256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331413256 | ||
| 003 | DE-627 | ||
| 005 | 20231225213415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.09.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331413256 | ||
| 035 | |a (NLM)34600019 | ||
| 035 | |a (PII)S0163-4453(21)00486-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lemenand, Olivier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 25.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2022 Jul;85(1):90-122. - PMID 35378141 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: We investigated the impact of the COVID-19 and national pandemic response on the epidemiology of Extended Spectrum Beta-Lactamase producing E. coli (ESBL-E.coli) in France | ||
| 520 | |a METHODS: Individual microbiology records from clinical laboratories were analyzed between 1 January 2019 to 31 December 2020. The ESBL-E.coli rates from clinical samples of patients in primary care and nursing home residents were compared before and after the general lockdown in March 2020, according to demographic and geographical characteristics. Interrupted time series analyses were performed to detect measurable changes in the trend of ESBL-E.coli rates | ||
| 520 | |a RESULTS: Records covering 793,954 E. coli isolates from 1022 clinical laboratories were analyzed. In primary care, 3.1% of E. coli isolates from clinical samples were producing ESBL before March 2020 and 2.9% since May 2020 (p < 0.001). The proportion of ESBL-E.coli decreased significantly among urine cultures, females, age categories 5-19, 40-64, > 65 year-old, and in the North, West, East and South-East regions. In nursing home, the ESBL-E.coli rate was 9.3% (monthly rate min-max: 6.5-10.5%) before March 2020 and 8.3% (7.2-9.1%) since May 2020 (p < 0.001). The reduction rate accelerated from -0.04%/month to -0.22%/month from May 2020 (p < 0.001) | ||
| 520 | |a CONCLUSION: Investigation of factors that led to the decreased proportion of ESBL-E.coli during the COVID-19 pandemic is urgently needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ESBL-E.coli | |
| 650 | 4 | |a Nursing homes | |
| 650 | 4 | |a Outpatient | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a Coeffic, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Thibaut, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Colomb Cotinat, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Caillon, Jocelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Birgand, Gabriel |e verfasserin |4 aut | |
| 700 | 0 | |a Clinical Laboratories of PRIMO Network. Nantes, France. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 83(2021), 6 vom: 12. Dez., Seite 664-670 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2021 |g number:6 |g day:12 |g month:12 |g pages:664-670 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.09.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2021 |e 6 |b 12 |c 12 |h 664-670 | ||